Latest Updates

Study

Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus

Share this article
Study

Latest Updates

News

Press Release

Diasome to Present Phase 2b Results from OPTI-2 Trial Evaluating HDV-Insulin Lispro in Type 1 Diabetes at ADA 86th Scientific Sessions

View Article
Press Release

Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes

View Article
Press Release

Diasome's CMO, Dr. Marc Penn, to Unveil Innovative Diabetes Research at ADA Scientific Sessions

View Article
View All